

DAFTAR PUSTAKA

- [1] M. Plummer, C. de Martel, J. Vignat, J. Ferlay, F. Bray, and S. Franceschi, "Global burden of cancers attributable to infections in 2012: a synthetic analysis," *Lancet Glob. Heal.*, vol. 4, no. 9, pp. e609–e616, Sep. 2016, doi: 10.1016/S2214-109X(16)30143-7.
- [2] "Cancer." <https://www.who.int/> (accessed Jan. 13, 2021).
- [3] "GLOBOCAN 2020: New Global Cancer Data | UICC." <https://www.uicc.org/> (accessed Jan. 14, 2021).
- [4] "(No Title)." <https://gco.iarc.fr/> (accessed Jan. 13, 2021).
- [5] G. Danaei, S. Vander Hoorn, A. D. Lopez, C. J. L. Murray, and M. Ezzati, "Causes of cancer in the world: Comparative risk assessment of nine behavioural and environmental risk factors," *Lancet*, 2005, doi: 10.1016/S0140-6736(05)67725-2.
- [6] "Cancer Causes." <https://stanfordhealthcare.org> (accessed Mar. 03, 2021).
- [7] A. A. Osman, A. Lindemann, L. Wang, S. J. Frank, and J. N. Myers, "Targeting TP53 to augment therapeutic response in head and neck cancer," in *Improving the Therapeutic Ratio in Head and Neck Cancer*, Elsevier, 2020, pp. 65–88.
- [8] "Indonesia." <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf> (accessed Mar. 01, 2021).
- [9] "Lip, oral cavity," 2020. Accessed: Mar. 01, 2021. [Online]. Available: <https://gco.iarc.fr/today>.
- [10] C. Kirsch, "Oral cavity cancer," *Top. Magn. Reson. Imaging*, vol. 18, no. 4, pp. 269–280, 2007, doi: 10.1097/RMR.0b013e3181572caa.



- [11] P. H. Montero and S. G. Patel, “Cancer of the Oral Cavity,” *Surg. Oncol. Clin. N. Am.*, vol. 24, no. 3, pp. 491–508, 2015, doi: 10.1016/j.soc.2015.03.006.
- [12] P. Nygren, “What is cancer chemotherapy?,” 2009, doi: 10.1080/02841860151116204.
- [13] “Chemotherapy Side Effects.”
- [14] J. R. Robbins, J. M. Longo, and M. Straza, “Radiation therapy,” in *Cancer Regional Therapy: HAI, HIPEC, HILP, ILI, PIPAC and Beyond*, Springer International Publishing, 2019, pp. 461–479.
- [15] W. A. G. Sauerwein, A. Wittig, R. Moss, and Y. Nakagawa, *Neutron capture therapy: Principles and applications*. 2012.
- [16] “Neutron Source | Japanese Society of Neutron Capture Therapy.” <http://www.jsnct.jp/> (accessed Jan. 14, 2021).
- [17] K. Niita *et al.*, “Particle and Heavy Ion Transport code System.”
- [18] T. Sato *et al.*, “Features of Particle and Heavy Ion Transport code System (PHITS) version 3.02,” *J. Nucl. Sci. Technol.*, vol. 55, no. 6, pp. 684–690, Jun. 2018, doi: 10.1080/00223131.2017.1419890.
- [19] D. Krstić and D. Nikezić, “Input files with ORNL-mathematical phantoms of the human body for MCNP-4B,” *Comput. Phys. Commun.*, vol. 176, no. 1, pp. 33–37, Jan. 2007, doi: 10.1016/j.cpc.2006.06.016.
- [20] H. Koivunoro, L. Kankaanranta, T. Seppälä, A. Haapaniemi, A. Mäkitie, and H. Joensuu, “Boron neutron capture therapy for locally recurrent head and neck squamous cell carcinoma: An analysis of dose response and survival,” *Radiother. Oncol.*, vol. 137, pp. 153–158, 2019, doi: 10.1016/j.radonc.2019.04.033.



- [21] H. Yu, Y. H. Liu, T. Lin, and L. Wang, “BNCT treatment planning of recurrent head-and-neck cancer using THORplan,” *Appl. Radiat. Isot.*, vol. 69, no. 12, pp. 1907–1910, 2011, doi: 10.1016/j.apradiso.2011.02.041.
- [22] D. N. I. Syamputra, “Analisis Dosis Pengobatan BNCT pada Kanker Rhabdomyosarcoma di Kepala dan Leher dengan PHITS Code,” 2018.
- [23] I. M. Ardana, “Optimasi Desain Kolimator dan Dosimetri Terapi Kanker Sarkoma Jaringan Lunak pada Leher dan Kepala dengan Boron Neutron Capture Therapy untuk Sumber Neutron Cyclotron 30 MeV Menggunakan Program Monte Carlo N Particle X,” pp. 1–27, 2015.
- [24] Z. K. Roesch and P. Tadi, *Anatomy, Head and Neck, Neck*. StatPearls Publishing, 2019.
- [25] S. Marur and A. A. Forastiere, “Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment,” *Mayo Clinic Proceedings*, vol. 91, no. 3. Elsevier Ltd, pp. 386–396, Mar. 01, 2016, doi: 10.1016/j.mayocp.2015.12.017.
- [26] S. B. Chinn and J. N. Myers, “Oral Cavity Carcinoma: Current Management, Controversies, and Future Directions,” *J Clin Oncol*, vol. 33, pp. 3269–3276, 2015, doi: 10.1200/JCO.2015.61.2929.
- [27] *AJCC Cancer Staging Manual*. 2017.
- [28] S. F. Worrall, “TNM Classification of Malignant Tumours.,” *Br. J. Oral Maxillofac. Surg.*, 2000, doi: 10.1054/bjom.1999.0055.
- [29] PDQ Screening and Prevention Editorial Board, *Oral Cavity and Oropharyngeal Cancer Screening (PDQ®): Patient Version*. 2002.
- [30] S. Chumber and N. Shukla, “Oral Cavity and Tongue,” *Essentials Surg.*, no. March, pp. 640–650, 2004, doi: 10.5005/jp/books/10298_35.



- [31] I. H. Kim and H. Myoung, "Squamous cell carcinoma of the buccal mucosa involving the masticator space: A case report," *J. Korean Assoc. Oral Maxillofac. Surg.*, 2017, doi: 10.5125/jkaoms.2017.43.3.191.
- [32] C. D. Jacobs, M. J. Moravan, J. Choe, R. Kahmke, Y. Mowery, and J. K. Salama, *Oral cavity cancer: Diagnosis and treatment*, 3rd ed. Elsevier Inc., 2018.
- [33] "Buccal mucosa and Masticator space anatomy."
<https://medicine.uiowa.edu> (accessed Mar. 01, 2021).
- [34] T. Basu and N. Bhaskar, "Overview of Important 'Organs at Risk' (OAR) in Modern Radiotherapy for Head and Neck Cancer (HNC)," *Cancer Surviv.*, Jan. 2019, doi: 10.5772/INTECHOPEN.80606.
- [35] N. Rosyida, "Pengukuran Laju Dosis Paparan Radiasi EKsternal Dalam Radioterapi RSUD Dr. Saiful Anwar Malang," Jul. 2016, Accessed: Jul. 26, 2021. [Online]. Available:
[http://download.garuda.ristekdikti.go.id/article.php?article=617833&val=7341&title=Measurement of External Radiation Dose Rate in Radiotherapy Area at dr Saiful Anwar General Hospital Malang](http://download.garuda.ristekdikti.go.id/article.php?article=617833&val=7341&title=Measurement%20of%20External%20Radiation%20Dose%20Rate%20in%20Radiotherapy%20Area%20at%20dr%20Saiful%20Anwar%20General%20Hospital%20Malang).
- [36] P. Rinard, "Neutron Interactions with Matter." in *Passive Nondestructive Assay of Nuclear Materials*, ed. U.S. Nuclear Regulatory Commission, NUREG/CR-5550.
- [37] E. B. Podgorsak, *Radiation Physics for Medical Physicists*. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010.
- [38] K. Nedunchezian, N. Aswath, M. Thiruppathy, and S. Thirugnanamurthy, "Boron neutron capture therapy - a literature review," *Journal of Clinical and Diagnostic Research*, vol. 10, no. 12. Journal of Clinical and Diagnostic Research, pp. ZE01–ZE04, Dec. 01, 2016, doi: 10.7860/JCDR/2016/19890.9024.



- [39] H. Fukuda *et al.*, “Boron neutron capture therapy (BNCT) for malignant melanoma with special reference to absorbed doses to the normal skin and tumor,” *Australas. Phys. Eng. Sci. Med.*, 2003, doi: 10.1007/BF03178777.
- [40] M. E. Lomax, L. K. Folkes, and P. O’Neill, “Biological consequences of radiation-induced DNA damage: Relevance to radiotherapy,” *Clin. Oncol.*, vol. 25, no. 10, pp. 578–585, 2013, doi: 10.1016/j.clon.2013.06.007.
- [41] R. F. Barth, P. Mi, and W. Yang, “Boron delivery agents for neutron capture therapy of cancer,” *Cancer Commun.*, vol. 38, no. 1, pp. 1–15, Jun. 2018, doi: 10.1186/s40880-018-0299-7.
- [42] R. F. Barth, J. A. Coderre, M. G. H. Vicente, and T. E. Blue, “Boron neutron capture therapy of cancer: Current status and future prospects,” *Clinical Cancer Research*, vol. 11, no. 11, pp. 3987–4002, Jun. 01, 2005, doi: 10.1158/1078-0432.CCR-05-0035.
- [43] M. A. Dymova, S. Y. Taskaev, V. A. Richter, and E. V. Kuligina, “Boron neutron capture therapy: Current status and future perspectives,” *Cancer Communications*. 2020, doi: 10.1002/cac2.12089.
- [44] A. H. Soloway, H. Hatanaka, and M. A. Davis, “Penetration of Brain and Brain Tumor. V II. Tumor-Binding Sulfhydryl Boron Compounds,” *J. Med. Chem.*, vol. 10, no. 4, pp. 714–717, 1967, doi: 10.1021/jm00316a042.
- [45] K. H. N. Mahmud, “Analisis Dosis Boron Neutron Capture Therapy (Bnct) Pada Kanker Otak (Glioblastoma Multiform) Menggunakan Mcnpx-Code Dengan Sumber Neutron Dari Kolimator Kolom Termal Reaktor Kartini,” 2017.
- [46] E. B. Podgoršak, “Interactions of Neutrons with Matter,” Springer, Berlin, Heidelberg, 2009, pp. 429–449.
- [47] IAEA, “Current status of neutron capture therapy,” *Iaea*, 2001, no. May,



pp. 75–77, 2001.

- [48] D. L. Chichester and J. D. Simpson, “Compact accelerator neutron generators,” *Industrial Physicist*. 2003.
- [49] International Atomic Energy Agency, “Cyclotron Produced Radionuclides: Principles and Practice,” *Cyclotr. Prod. Radionuclides Princ. Pract.*, 2008.
- [50] Yunasfi, Mujiono, D. Irwanti, and Hanifa, “Penggunaan Akselerator untuk Terapi di Indonesia,” 2003.
- [51] M. Suzuki, “Boron neutron capture therapy (BNCT): a unique role in radiotherapy with a view to entering the accelerator-based BNCT era,” *Int. J. Clin. Oncol.*, vol. 25, no. 1, pp. 43–50, 2020, doi: 10.1007/s10147-019-01480-4.
- [52] T. Mitsumoto *et al.*, “Cyclotron-based neutron source for BNCT,” *AIP Conf. Proc.*, vol. 1525, no. 1, pp. 319–322, 2013, doi: 10.1063/1.4802341.
- [53] Y. Kiyanagi, Y. Sakurai, H. Kumada, and H. Tanaka, “Status of accelerator-based BNCT projects worldwide,” 2019, doi: 10.1063/1.5127704.
- [54] J. W. Hopewell, G. M. Morris, A. Schwint, and J. A. Coderre, “The radiobiological principles of boron neutron capture therapy: A critical review,” *Appl. Radiat. Isot.*, vol. 69, no. 12, pp. 1756–1759, 2011, doi: 10.1016/j.apradiso.2011.04.019.
- [55] F. Basyid and K. Adi, “SEGMENTASI CITRA MEDIS UNTUK PENGENALAN OBJEK KANKER MENGGUNAKAN METODE ACTIVE CONTOUR,” 2014.
- [56] A. K. Berthelsen *et al.*, “What’s new in target volume definition for radiologists in ICRU Report 71? How can the ICRU volume definitions be integrated in clinical practice?,” *Cancer Imaging*, vol. 7, no. 1. BioMed



- Central, pp. 104–116, 2007, doi: 10.1102/1470-7330.2007.0013.
- [57] A. M. Johansen, “Monte Carlo Methods,” *Int. Encycl. Educ.*, pp. 296–303, Jan. 2010, doi: 10.1016/B978-0-08-044894-7.01543-8.
- [58] I. Kawrakow, “The Monte Carlo Simulation of Radiation Transport NRC-CNRC.”
- [59] “Overview.” <https://phits.jaea.go.jp/Overview.html> (accessed Feb. 09, 2021).
- [60] Tatsuhiko Sato et. al, “Ver. 3.22 User’s Manual.”
- [61] D. Krstić and D. Nikezić, “Input files with ORNL-mathematical phantoms of the human body for MCNP-4B,” *Comput. Phys. Commun.*, vol. 176, no. 1, pp. 33–37, 2007, doi: 10.1016/j.cpc.2006.06.016.
- [62] U. S. Customs, B. Protection, D. Nuclear, and D. Office, “Compendium of Material Composition Data for Radiation Transport Modeling,” 2011, [Online]. Available: www.pnnl.gov/main/publications/external/technical_reports/pnnl-15870rev1.pdf.
- [63] M. D. R. Puspita, “Analisis Dosis Radiasi Terapi Kanker Serviks dengan Boron Neutron Capture Therapy (BNCT) Berbasis Particle and Heavy Ion Transport Code System (PHITS),” 2021.
- [64] J. Capala, J. A. Coderre, and A. D. Chanana, “A Treatment Planning Comparison of BPA-or BSH-based BNCT of Malignant Gliomas.”
- [65] Mostafa Alizade- Harakiyan, A. G. Jangjoo, Tohid Jafari-Koshki, Ali Fatemi, and A. Mesbahi, “Radiobiological modeling of acute esophagitis after radiation therapy of head, neck, and thorax tumors: The influence of chemo-radiation,” *J. Cancer Res. Ther.*, vol. 14, no. 7, pp. 1525–1534, 2018, doi: 10.4103/jcrt.JCRT.



- [66] M. A. Pisarev, M. A. Dagrosa, and G. J. Juvenal, “Boron neutron capture therapy in cancer: Past, present and future,” *Arquivos Brasileiros de Endocrinologia e Metabologia*, vol. 51, no. 5. Sociedade Brasileira de Endocrinologia e Metabologia, pp. 852–856, 2007, doi: 10.1590/S0004-27302007000500024.
- [67] K. N. Loganovsky *et al.*, “Radiation-Induced Cerebro-Ophthalmic Effects in Humans,” doi: 10.3390/life10040041.
- [68] M. A. Garabalino *et al.*, “Boron biodistribution for BNCT in the hamster cheek pouch oral cancer model: Combined administration of BSH and BPA,” *Appl. Radiat. Isot.*, vol. 88, pp. 64–68, 2014, doi: 10.1016/j.apradiso.2013.11.118.

